摘要
目的探讨曲妥珠单抗耐药晚期乳腺癌患者应用吡咯替尼的临床效果。方法选择该院2018年10月—2021年2月收治的58例曲妥珠单抗耐药晚期乳腺癌患者作为研究对象,借助随机抽签方式将患者分为对照组与观察组,每组29例。对照组应用多西他赛化疗联合曲妥珠单抗靶向治疗,观察组应用多西他赛化疗联合吡咯替尼靶向治疗。对比两组患者治疗后的临床效果、肿瘤标志物及不良反应发生情况。结果观察组临床治疗总有效率为82.75%,明显高于对照组的55.17%,差异有统计学意义(χ^(2)=5.155,P=0.023);治疗后,观察组患者CA153、CEA及TPS分别为(7.11±1.04)μg/L、(10.21±3.69)U/mL、(14.06±3.12)μg/L,显著优于对照组,差异有统计学意义(t=15.787、10.962、5.605,P<0.001);观察组不良反应发生率(13.79%)与对照组(34.48%)比较,差异无统计学意义(χ^(2)=3.385,P>0.05)。结论曲妥珠单抗耐药晚期乳腺癌患者应用吡咯替尼进行治疗,可以提升疾病控制率,有利于优化患者肿瘤标志物指标,对患者预后具有积极意义。
Objective To investigate the clinical effect of pyrotinib in patients with trastuzumab-resistant advanced breast cancer.Methods 58 patients with trastuzumab-resistant advanced breast cancer admitted to the hospital from October 2018 to February 2021 were selected as the study objects.The patients were divided into a control group and an observation group by random drawing,with 29 cases in each group.The control group received docetaxel chemotherapy combined with trastuzumab targeted therapy,while the observation group received docetaxel chemotherapy combined with pyrotinib targeted therapy.The clinical effects,tumor markers and the occurrence of adverse reactions were compared between the two groups of patients after treatment.Results The total effective rate of clinical treatment in the observation group was 82.75%,which was significantly higher than 55.17%in the control group,and the difference was statistically significant(χ^(2)=5.155,P=0.023).CA153,CEA and TPS in observation group were(7.11±1.04)μg/L,(10.21±3.69)U/mL,and(14.06±3.12)μg/L,respectively,which were significantly better than those of the control group,and the difference was statistically significant(t=15.787,10.962,5.605,P<0.001).There was no statistically significant difference in adverse reactions between the observation group(13.79%)and the control group(34.48%)(χ^(2)=3.385,P>0.05).Conclusion Pyrotinib can improve the disease control rate in patients with trastuzumab-resistant advanced breast cancer.It is beneficial to optimize the patient's tumor marker index and has positive significance for the patient's prognosis.
作者
李晓通
杜红梅
LI Xiaotong;DU Hongmei(The First Department of Oncology,Daqing People's Hospital,Daqing,Heilongjiang Province,163000 China;Department of Health and Nursing,Qiqihar Engineering College,Qiqihar,Heilongjiang Province,161000 China)
出处
《系统医学》
2022年第9期175-178,共4页
Systems Medicine
关键词
曲妥珠单抗
耐药
晚期乳腺癌
吡咯替尼
不良反应
肿瘤标志物
Trastuzumab
Drug resistance
Advanced breast cancer
Pyrotinib
Adverse reactions
Tumor markers
